...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of diabetes. >Effect of basal insulin supplement therapy on diabetic retinopathy in short‐duration type 2 diabetes: A one‐year randomized parallel‐group trial
【24h】

Effect of basal insulin supplement therapy on diabetic retinopathy in short‐duration type 2 diabetes: A one‐year randomized parallel‐group trial

机译：基础胰岛素补充疗法的效果糖尿病性视网膜病变在短时间2型糖尿病:一个一年随机平行组试验

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Abstract Background In this study, we compared the effect on diabetic retinopathy (DR) between oral antidiabetic drugs (OADs) alone and in combination with basal insulin‐supported OADs therapy (BOT). [Correction added on 11 November 2019, after first online publication: In Abstract under Background section, “DR” has been corrected into “diabetic retinopathy (DR)”.] Methods Between January 2015 and January 2018, this study enrolled 290 patients (age 18‐65?years) with diabetes duration between 0 and 5 years. Patients were randomly assigned to receive OADs or BOT after 14?days intensive insulin treatment. Examinations were performed at the beginning and end of the study. Results Fewer patients developed DR in the BOT than OADs group (8 [6.06%] vs 12 [8.3%], respectively), and all cases of DR were non‐proliferative. Blood glucose concentrations were higher in the BOT than OADs group at the 3rd month, but lower in the former at the 6th and 12th month. The rate of reaching target HbA1c ≤7% was lower in the BOT than OADs group at the 3rd month (63.6% vs 72.2%, respectively), similar between the two groups at the 6th month (60.6% vs 66.6%, respectively) and higher in the BOT group at the 12th month (75.0% vs 61.1%, respectively). The SD of fasting blood glucose (FBG), coefficient of variation of FBG, SD of blood glucose (SDBG), and mean amplitude of glycemic excursions were lower in the BOT than OADs group. Changes in the levels of three cytokines (interleukin [IL]‐1β, IL‐6, and IL‐17α) were significantly less in the BOT than OADs group. Conclusions Twelve months of BOT decreased the incidence of DR in short‐duration type 2 diabetes by reducing glycemia more effectively, stably, and completely than OADs alone.
机译：抽象的背景在这项研究中,我们比较了口腔之间对糖尿病性视网膜病变(DR)的影响(全尺寸),抗糖尿病的药物结合基础胰岛素量支持外形尺寸治疗(机器人)。2019年第一次在线出版物:在抽象的在背景部分,“博士”已经被修正“糖尿病性视网膜病变(DR)”。2015年1月至2018年1月,这项研究招收了290名患者(18岁还是65 ?年)糖尿病持续时间在0和5年之间。被随机分配接受外形尺寸还是机器人经过14 ?考试开始时进行研究结束。博士开发的机器人比全尺寸组(8(6.06%)和12个(8.3%),分别),和所有例博士非增生性。浓度比全尺寸的机器人在第三个月组,但在前低6日和12月。目标糖化血红蛋白低的机器人比全尺寸≤7%组3月(63.6% vs 72.2%,分别),两组之间的相似6月(分别为60.6%和66.6%)更高的机器人小组12月(75.0%分别对61.1%)。血糖(FBG)、变异系数的光纤光栅,SD的血糖(SDBG)和平均振幅血糖在机器人比低外形尺寸。[他]‐1β细胞因子(interleukin,, and‐‐6 - 17α)在机器人大大小于外形尺寸吗组。博士的发病率在短时间2型糖尿病患者更有效地降低血糖,比全尺寸稳定,完全孤独。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号